Effect of Tandem Autologous Stem Cell Transplantation on Survival in Pediatric Patients with High-risk Solid Tumors in South China

Overview

Journal World J Stem Cells

Publisher Baishideng Publishing Group

Date 2025 Mar 10

PMID 40061267

Authors

Zi-Yan Luo

Li-Qun Fan

Wen-Ling Guo

Jian-Ping Yang

Zhuo-Yan Li

Yong-Xian Huang

Hua Jiang

Xiao-Hong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Despite advances in treatment, the prognosis for patients with high-risk pediatric solid tumors remains dismal. Tandem autologous stem cell transplantation (ASCT) offers promise for improving outcomes in these patients. This study aimed to examine the efficacy and prognostic factors of tandem ASCT in pediatric patients with high-risk solid tumors.

Aim: To determine the survival outcomes and prognostic factors in pediatric patients with high-risk solid tumors undergoing tandem ASCT.

Methods: A total of 40 pediatric patients with high-risk solid tumors treated from March 2015 to August 2022 were included in this retrospective study. The diagnoses of the patients included neuroblastoma, germ cell tumors, atypical teratoid/rhabdoid tumor, medulloblastoma, and pineoblastoma. After induction chemotherapy, all patients received tandem ASCT and were allocated into two groups (group A and group B) based on high-dose chemotherapy regimens. Prognostic relevance was evaluated by examining patient characteristics, such as sex, age, lactate dehydrogenase levels, primary site, the number of metastatic sites, and bone marrow involvement.

Results: The median follow-up duration since the first ASCT was 24 months (range: 1-91 months), with 5-year overall survival (OS) and event-free survival (EFS) rates of 73% and 70%, respectively, for the entire cohort. The 3-year OS rates were 67% for group A and 87% for group B ( = 0.29), with corresponding 3-year EFS rates of 67% and 79% ( = 0.57). Among neuroblastoma patients, the 5-year OS and EFS were 69% and 63% ( = 0.23). Univariable analysis revealed a notable association of age ≥ 36 months and elevated lactate dehydrogenase level at diagnosis with poorer OS. Despite acute adverse effects, all patients demonstrated good tolerance to the treatment, with no occurrences of transplant-related mortality.

Conclusion: Tandem ASCT demonstrates promising survival outcomes for patients with high-risk solid tumors, particularly neuroblastoma, with manageable toxicity and no transplant-related mortality.

References

George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24(18):2891-6. DOI: 10.1200/JCO.2006.05.6986. View

Kobayashi R, Inoue M, Takahashi Y, Kikuta A, Ogawa A, Koga Y . Autologous Stem Cell Transplantation for Children With Renal Tumors, and Adults With Wilms Tumor: Retrospective Analysis of the Japanese Transplant Registry Unified Management Program. J Pediatr Hematol Oncol. 2020; 42(4):251-255. DOI: 10.1097/MPH.0000000000001779. View

Najafi M, Majidpoor J, Toolee H, Mortezaee K . The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol. 2021; 35(11):e22900. DOI: 10.1002/jbt.22900. View

Alnasser S, Alharbi K, Almutairy A, Almutairi S, Alolayan A . Autologous Stem Cell Transplant in Hodgkin's and Non-Hodgkin's Lymphoma, Multiple Myeloma, and AL Amyloidosis. Cells. 2023; 12(24). PMC: 10741865. DOI: 10.3390/cells12242855. View

Seif A, Naranjo A, Baker D, Bunin N, Kletzel M, Kretschmar C . A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013; 48(7):947-52. PMC: 3638062. DOI: 10.1038/bmt.2012.276. View

Kreissman S, Seeger R, Matthay K, London W, Sposto R, Grupp S . Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013; 14(10):999-1008. PMC: 3963485. DOI: 10.1016/S1470-2045(13)70309-7. View

Lupo P, Spector L . Cancer Progress and Priorities: Childhood Cancer. Cancer Epidemiol Biomarkers Prev. 2020; 29(6):1081-1094. PMC: 9400945. DOI: 10.1158/1055-9965.EPI-19-0941. View

Riley R, Heney D, Jones D, Sutton A, Lambert P, Abrams K . A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004; 10(1 Pt 1):4-12. DOI: 10.1158/1078-0432.ccr-1051-2. View

Tian C, Li Y, Liu S, Chen Z, Zhang Y, Yu Y . Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients. Sci Rep. 2021; 11(1):4273. PMC: 7895978. DOI: 10.1038/s41598-021-81944-8. View

10.

Cangemi G, Reggiardo G, Barco S, Barbagallo L, Conte M, DAngelo P . Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther. 2012; 5:417-23. PMC: 3514851. DOI: 10.2147/OTT.S36366. View

11.

Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N . Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant. 1999; 24(6):609-15. DOI: 10.1038/sj.bmt.1701950. View

12.

Guo W, Zhan Y, Mery D, Siegel E, Sun F, Cheng Y . Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood Cancer J. 2024; 14(1):30. PMC: 10866867. DOI: 10.1038/s41408-024-00998-9. View

13.

Koo J, Silverman S, Nuechterlein B, Keating A, Verneris M, Foreman N . Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors. Bone Marrow Transplant. 2019; 54(10):1605-1613. PMC: 6957458. DOI: 10.1038/s41409-019-0479-3. View

14.

Zhang Y, Zhang W, Huang D, Wang Y, Hu H, Zhi T . Prognostic factors for intermediate- or high-risk neuroblastomas in children in China. BMC Pediatr. 2023; 23(1):617. PMC: 10699076. DOI: 10.1186/s12887-023-04258-w. View

15.

Guo W, Zhan A, Mery D, Munshi M, Makhoul O, Baily C . Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. Blood Adv. 2023; 7(21):6676-6684. PMC: 10637884. DOI: 10.1182/bloodadvances.2023011096. View

16.

Kitko C, Bollard C, Cairo M, Chewning J, Fry T, Pulsipher M . Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation. Pediatr Blood Cancer. 2023; 70 Suppl 6:e30577. PMC: 10527977. DOI: 10.1002/pbc.30577. View

17.

Adra N, Abonour R, Althouse S, Albany C, Hanna N, Einhorn L . High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. J Clin Oncol. 2016; 35(10):1096-1102. PMC: 5455354. DOI: 10.1200/JCO.2016.69.5395. View

18.

Olson T, Pollack M, Davila Saldana B, Patel A . Hospital survival following pediatric HSCT: changes in complications, ICU therapies and outcomes over 10 years. Front Pediatr. 2023; 11:1247792. PMC: 10601648. DOI: 10.3389/fped.2023.1247792. View

19.

Granger M, Naranjo A, Bagatell R, Dubois S, McCune J, Tenney S . Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021; 27(6):490.e1-490.e8. PMC: 8855886. DOI: 10.1016/j.jtct.2021.03.006. View

20.

Bagatell R, Park J, Acharya S, Aldrink J, Allison J, Alva E . Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024; 22(6):413-433. DOI: 10.6004/jnccn.2024.0040. View